Journal of Dermatology and Dermatologic Diseases

Department of Medical and Surgical Dermatology, SimcoDerm Medical and Surgical Dermatology Centre, Royal Court Medical Centre, Barrie, Canada

Publications

• Research Article   
  Efficacy Of Zyclara Cream (3.75% Imiquimod) Once A Day For One Week In Actinic Keratosis Of The Face: Results From A Non-randomized, Open-label, Prospective Study
  Author(s): Natalee Schors*, Pouria Keshoofy and Maryam Shayesteh Alam
  
  Scope: Actinic keratoses are premalignant lesions of the epidermis that result from ultraviolet radiation exposure and can advance into squamous cell carcinoma. 3.75% imiquimod cream, available as Zyclara, is an immune response modifier that has been demonstrated to be an effective alternative to conventional treatment for actinic keratosis. The objective of this study was to collect data on ten patients with multiple non-hypertrophic facial actinic keratoses following the daily week long topical application Zyclara cream, in order to analyze its effectiveness and safety in a shorter treatment duration than standard approaches. Methodology: This non-randomized, open-label, prospective study enrolled ten participants 18 years of age or older with actinic keratoses presenting on their face or scalp and were instructed to apply top.. Read More»
  DOI: 10.37421/2684-4281.2022.9.350

  Abstract HTML PDF